Compass Pathways Plc ADR (CMPS) Stock Price, Quote & News

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company...

Industry: Medical Care Facilities

Sector: Healthcare

Phone: 44 716 6766461

Website: compasspathways.com

Address:

33 Broadwick Street, London, United Kingdom

InvestorWisdom Jun. 29 at 5:02 AM

$CMPS is working beautifully. Closed at the highest price since 2022… and the wind at their back will grow stronger as we near the end of the year. See DD below…

0 · Reply

thevert123 Jun. 29 at 3:09 AM

$CMPS we got green futures as of now. Hoping to see a continuation. I think $15 is going to be a hard zone to break. Maybe, maybe not. Excited to see what this week brings. Love to see 16-17s. Possibly next week news gets dropped. Little nervous, i won't lie. We are bullish, but at haven't crossed the finish line yet. Love to see a better than expected report, but i think a good, normal report takes us into the 20s. From everything i seen, i think 3 billion mkt cap (rougly $22 area) is probably going to be where we land for awhile. Possible hype train forming into fda approval. Again, id love to be wrong, but I'm trying to stay grounded. Rather be pleasantly surprised then disappointed. Either way, we making money💪🚀

1 · Reply

twiggs462 Jun. 29 at 1:27 AM

$CMPS $DFTX $ATAI Great PBS video... https://youtu.be/g9z1bqK1sco?is=4108rA4Krw_IiD9u

0 · Reply

AllStar_ADP Jun. 28 at 11:20 PM

$CMPS Anyone else grow their own schrooms after investing in CMPS?

1 · Reply

Zeliko13 Jun. 28 at 10:54 PM

$CMPS https://www.medicaldaily.com/psilocybin-fda-approval-2026-compass-pathways-comp360-treatment-resistant-depression-475822

0 · Reply

They_Call_Me_Tater_Salad Jun. 28 at 4:07 PM

$CMPS I struggle to find a problem with this company. Durability of COMP360 appears to be magnitudes better than Spravato… Drugs are not prescribed off label to treat worse conditions. They are prescribed down off label. Spravato wont be prescribed for TRD, but COMP360 can be prescribed for MDD (off label). So many catalysts upcoming. Fully expect up to several rerating episodes in the next 6-12 months.

2 · Reply

wizkid1774 Jun. 28 at 11:54 AM

$CMPS time to buy baby buy.

0 · Reply

Waldo_5150 Jun. 28 at 11:21 AM

$CMPS ....... Expect the same for COMP360 - CEO has said they are already working with Insurers setting up Billing Codes .... Spravato is widely covered by insurance in the United States as of 2026, because it is a FDA-approved medication ... Blue Cross Blue Shield Aetna Cigna Medicare Medicaid UnitedHealthcare Others (Kaiser, etc.) ................

0 · Reply

wat92098 Jun. 28 at 9:14 AM

$CMPS Not gonna lie, this stock has brought me joy!!!! Longish fide, but soooooo worth it! $$$

0 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

3 · Reply

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

DFTX

2026-06-26T11:55:16.000Z - 3 days ago

Compass Pathways price target raised to $20 from $18 at Canaccord

2026-06-24T16:15:10.000Z - 4 days ago

COMPASS Pathways PLC put volume heavy and directionally bearish

Jun 24, 2026, 7:41 AM EDT - 5 days ago

3 Companies Redefining Healthcare Innovation

CRSP VRTX

Jun 5, 2026, 6:30 AM EDT - 24 days ago

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2026, 10:00 AM EDT - 27 days ago

Why Trump Is Pushing Psychedelics To Treat Mental Illness

May 31, 2026, 8:00 AM EDT - 4 weeks ago

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare

May 28, 2026, 6:30 AM EDT - 4 weeks ago

Compass Pathways Elects Kathleen Tregoning to Board of Directors

May 26, 2026, 6:30 AM EDT - 4 weeks ago

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

May 19, 2026, 10:00 AM EDT - 5 weeks ago

COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-15T15:28:25.000Z - 6 weeks ago

Compass Pathways price target raised to $20 from $12 at Maxim

2026-05-14T18:50:44.000Z - 6 weeks ago

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

ATAI CMND DFTX ENVB GHRS MIRA NRXP

2026-05-14T16:52:26.000Z - 6 weeks ago

Compass Pathways price target raised to $17 from $16 at Morgan Stanley

May 14, 2026, 6:30 AM EDT - 6 weeks ago

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

COMPASS Pathways Earnings release: Q1 2026

2026-05-13T11:23:45.000Z - 6 weeks ago

Compass Pathways reports Q1 EPS (30c), consensus (31c)

2026-05-13T11:19:03.000Z - 6 weeks ago

Compass Pathways expects cash position to fund the company into 2028

May 13, 2026, 7:00 AM EDT - 6 weeks ago

COMPASS Pathways Slides: Investor presentation

May 13, 2026, 6:30 AM EDT - 6 weeks ago

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

2026-05-07T18:24:07.000Z - 7 weeks ago

Psychedelic: Jefferies initiates Compass Pathways with a Buy rating

CMND ENVB JNJ NRXP SILO

May 6, 2026, 6:30 AM EDT - 7 weeks ago

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

2026-05-03T23:55:09.000Z - 2 months ago

Compass Pathways initiated with a Buy at Jefferies

JNJ

2026-04-30T18:56:54.000Z - 2 months ago

Psychedelic: FDA awards Compass Pathways priority review voucher

CMND HELP SILO

Apr 27, 2026, 11:00 AM EDT - 2 months ago

COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum

2026-04-24T17:41:05.000Z - 2 months ago

Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360

2026-04-24T14:45:52.000Z - 2 months ago

Compass Pathways announces FDA granted NDA rolling review request

Apr 24, 2026, 10:37 AM EDT - 2 months ago

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

2026-04-24T12:57:10.000Z - 2 months ago

Compass Pathways initiated with a Buy at B. Riley

2026-04-21T10:54:16.000Z - 2 months ago

Compass Pathways enters collaboration with Osmind

Apr 21, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026, 2:05 PM EDT - 2 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 2 months ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI DFTX GHRS

Apr 20, 2026, 8:26 AM EDT - 2 months ago

Psychedelic stocks rally with Trump's support

ATAI DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 2 months ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 2 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI DFTX ENVB GHRS HELP

Apr 20, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Apr 18, 2026, 4:12 PM EDT - 2 months ago

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 15, 2026, 8:00 AM EDT - 2 months ago

COMPASS Pathways Proxy statement: Proxy filing

Apr 14, 2026, 12:45 PM EDT - 2 months ago

COMPASS Pathways Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026, 6:30 AM EDT - 2 months ago

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Mar 24, 2026, 7:30 AM EDT - 3 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Earnings release: Q4 2025

Mar 24, 2026, 7:00 AM EDT - 3 months ago

COMPASS Pathways Annual report: Q4 2025

Mar 18, 2026, 10:30 AM EDT - 3 months ago

COMPASS Pathways Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 6:30 AM EDT - 3 months ago

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Mar 3, 2026, 10:30 AM EST - 4 months ago

COMPASS Pathways Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:30 AM EST - 4 months ago

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Feb 24, 2026, 6:39 AM EST - 4 months ago

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Feb 18, 2026, 8:18 PM EST - 4 months ago

Compass Pathways Announces Pricing of $150 Million Public Offering

Feb 17, 2026, 4:06 PM EST - 4 months ago

Compass Pathways Launches Proposed $150.0 Million Public Offering

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Transcript: Study update

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Press release: Study update

Feb 17, 2026, 8:00 AM EST - 4 months ago

COMPASS Pathways Slides: Study update

Feb 17, 2026, 6:42 AM EST - 4 months ago

Compass Pathways' depression treatment meets main goal in late‑stage study

Feb 17, 2026, 6:30 AM EST - 4 months ago

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Feb 16, 2026, 8:00 AM EST - 4 months ago

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Feb 9, 2026, 5:01 PM EST - 4 months ago

COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Transcript: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Press release: KOL Event

Jan 7, 2026, 10:00 AM EST - 6 months ago

COMPASS Pathways Slides: KOL Event

Jan 7, 2026, 7:00 AM EST - 6 months ago

COMPASS Pathways Slides: Investor Presentation

Jan 7, 2026, 6:30 AM EST - 6 months ago

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Jan 6, 2026, 6:30 AM EST - 6 months ago

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Dec 9, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Dec 3, 2025, 1:30 PM EST - 7 months ago

COMPASS Pathways Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 10:00 AM EST - 7 months ago

COMPASS Pathways Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 20, 2025, 6:30 AM EST - 7 months ago

Compass Pathways to Participate in Two Investor Conferences in December

Nov 11, 2025, 10:40 AM EST - 8 months ago

COMPASS Pathways Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 6:30 AM EST - 8 months ago

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 9:30 AM EST - 8 months ago

COMPASS Pathways Slides: Investor Presentation

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

COMPASS Pathways Earnings release: Q3 2025

Nov 4, 2025, 6:45 AM EST - 8 months ago

Compass Pathways to expedite launch timing of its experimental depression therapy

Nov 4, 2025, 6:30 AM EST - 8 months ago

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Oct 30, 2025, 8:30 AM EDT - 8 months ago

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Oct 29, 2025, 6:30 AM EDT - 8 months ago

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Oct 28, 2025, 6:30 AM EDT - 8 months ago

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Sep 2, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Aug 27, 2025, 6:30 AM EDT - 10 months ago

Compass Pathways to Participate in Four Investor Conferences in September

Aug 12, 2025, 4:00 PM EDT - 11 months ago

COMPASS Pathways Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 11 months ago

COMPASS Pathways Quarterly report: Q2 2025

Jul 31, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 11 months ago

Compass Pathways Appoints Justin Gover to Board of Directors

Jul 22, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

Jul 10, 2025, 4:00 PM EDT - 1 year ago

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Jun 23, 2025, 8:12 AM EDT - 1 year ago

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Jun 23, 2025, 6:48 AM EDT - 1 year ago

Compass Pathways' depression drug succeeds late-stage trial

InvestorWisdom Jun. 29 at 5:02 AM

$CMPS is working beautifully. Closed at the highest price since 2022… and the wind at their back will grow stronger as we near the end of the year. See DD below…

0 · Reply

thevert123 Jun. 29 at 3:09 AM

1 · Reply

twiggs462 Jun. 29 at 1:27 AM

$CMPS $DFTX $ATAI Great PBS video... https://youtu.be/g9z1bqK1sco?is=4108rA4Krw_IiD9u

0 · Reply

AllStar_ADP Jun. 28 at 11:20 PM

$CMPS Anyone else grow their own schrooms after investing in CMPS?

1 · Reply

Zeliko13 Jun. 28 at 10:54 PM

$CMPS https://www.medicaldaily.com/psilocybin-fda-approval-2026-compass-pathways-comp360-treatment-resistant-depression-475822

0 · Reply

They_Call_Me_Tater_Salad Jun. 28 at 4:07 PM

2 · Reply

wizkid1774 Jun. 28 at 11:54 AM

$CMPS time to buy baby buy.

0 · Reply

Waldo_5150 Jun. 28 at 11:21 AM

0 · Reply

wat92098 Jun. 28 at 9:14 AM

$CMPS Not gonna lie, this stock has brought me joy!!!! Longish fide, but soooooo worth it! $$$

0 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

3 · Reply

Patriots1 Jun. 27 at 1:17 PM

$CMPS https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16053/compass-pathways-cmps-receives-a-buy-from-h-c-wainwright/

1 · Reply

Patriots1 Jun. 27 at 1:16 PM

$CMPS https://m.investing.com/news/analyst-ratings/canaccord-raises-compass-pathways-stock-price-target-on-phase-3-data-93CH-4762839?ampMode=1

0 · Reply

Waldo_5150 Jun. 27 at 10:37 AM

$CMPS ..... Some have asked , Why can't I just go buy the Raw Mushroom where's it legal in Colorado and Oregon ? You Can't - - Raw Mushroom: You still have to go to a State Clinic for treatment which is not covered by Insurance , cost between $1,000 - $4,000 Cannot legally buy raw psilocybin mushrooms on the internet in Oregon or Colorado — or anywhere else in the United States. "This is exactly why COMP360 will be a game changer for standard medical clinics. Healthcare systems don't want to operate under the weird legal loopholes, waivers, and consumer-protection headaches of the raw market — they want a standardized drug they can confidently prescribe without fear of a courtroom" ...............

1 · Reply

LurkerLongtime Jun. 27 at 1:11 AM

$ATAI $CMPS I have some buy orders for them when they do. Let's fuckin ride

0 · Reply

QuietlyAccumulating Jun. 27 at 12:57 AM

$CMPS $HELP These will be Huge for PTSD (Post Trump Stress Disorder).

3 · Reply

zmanx Jun. 27 at 12:06 AM

$CMPS up over 💯% in 2026 so far… this was my buy post for latecomers 👇🏾

2 · Reply

Waldo_5150 Jun. 26 at 11:08 PM

$CMPS ...... Why do we tend to harbor bad thoughts vs good ? - When negative experiences are severe, frequent, or prolonged, they can rewrite the brain's baseline. Instead of processing a bad event and moving on, the brain can get stuck in a loop of rumination. - That's were COMP360 can help rewrite and end the loop. .

1 · Reply